C2N Diagnostics, LLC Sustainability Profile
C2N Diagnostics, LLC, headquartered in the United States, is a pioneering company in the field of diagnostic testing, particularly focused on neurodegenerative diseases. Founded in 2012, C2N has established itself as a leader in the development of innovative biomarkers that aid in the early detection and management of conditions such as Alzheimer’s disease. The company’s flagship products, including the PrecivityAD™ test, are designed to provide clinicians with critical insights into patients' cognitive health, setting C2N apart in the competitive diagnostics landscape. With a commitment to advancing precision medicine, C2N Diagnostics has achieved significant milestones, including partnerships with leading research institutions and recognition for its contributions to the field. As a trusted name in neurodiagnostics, C2N continues to enhance patient care through its cutting-edge solutions.
DitchCarbon Score
How does C2N Diagnostics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
C2N Diagnostics, LLC's score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
C2N Diagnostics, LLC's reported carbon emissions
C2N Diagnostics, LLC, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that C2N Diagnostics may not have established formal commitments to reduce carbon emissions or may be in the early stages of developing such initiatives. In the context of the diagnostics industry, many companies are increasingly focusing on sustainability and climate action. However, without specific emissions data or reduction targets, it is challenging to assess C2N Diagnostics' position relative to industry standards. As the company progresses, it may consider adopting frameworks such as the Science Based Targets initiative (SBTi) to align its climate commitments with global climate goals.
How Carbon Intensive is C2N Diagnostics, LLC's Industry?
How Carbon Intensive is C2N Diagnostics, LLC's Location?
C2N Diagnostics, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
C2N Diagnostics, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
